Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 July 2018

Indication(s)

Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Psoriasis Academy

Psoriasis Academy

Learn about the burden of psoriasis, unmet needs, the tools used to assess severity and treatment response, what we know about the pathophysiology behind the condition and what the current guidelines say.

+ 1 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/004271
Orphan designation No
Date First Approved 10-11-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Janssen-Cilag International N.V.